<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-title>BMC Cancer</journal-title><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2407-9-212</article-id><article-id pub-id-type="pmid">19563658</article-id><article-id pub-id-type="doi">10.1186/1471-2407-9-212</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Longatto-Filho</surname><given-names>Adhemar</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>longatto@ecsaude.uminho.pt</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Pinheiro</surname><given-names>C&#x000e9;line</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>cpinheiro@ecsaude.uminho.pt</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Martinho</surname><given-names>Olga</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>olgamartinho@ecsaude.uminho.pt</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Moreira</surname><given-names>Marise AR</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>mmoreira@yahoo.com</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Ribeiro</surname><given-names>Luiz FJ</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>lfjribeiro@yahoo.com</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Queiroz</surname><given-names>Geraldo S</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>queirozg@gmail.com</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Schmitt</surname><given-names>Fernando C</given-names></name><xref ref-type="aff" rid="I5">5</xref><xref ref-type="aff" rid="I6">6</xref><email>fschmitt@ipatimup.pt</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Baltazar</surname><given-names>F&#x000e1;tima</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>fbaltazar@ecsaude.uminho.pt</email></contrib><contrib id="A9" corresp="yes" contrib-type="author"><name><surname>Reis</surname><given-names>Rui M</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>rreis@ecsaude.uminho.pt</email></contrib></contrib-group><aff id="I1"><label>1</label>Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal</aff><aff id="I2"><label>2</label>Instituto Adolfo Lutz, S&#x000e3;o Paulo, SP, Brazil</aff><aff id="I3"><label>3</label>Department of Pathology of the School of Medicine of the Federal University of Goi&#x000e1;s, Goi&#x000e2;nia, Go, Brazil</aff><aff id="I4"><label>4</label>Hospital Ara&#x000fa;jo Jorge, Goi&#x000e2;nia, Go, Brazil</aff><aff id="I5"><label>5</label>IPATIMUP, Porto, Portugal</aff><aff id="I6"><label>6</label>School of Medicine of the University of Porto, Porto, Portugal</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>29</day><month>6</month><year>2009</year></pub-date><volume>9</volume><fpage>212</fpage><lpage>212</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/9/212"/><history><date date-type="received"><day>23</day><month>12</month><year>2008</year></date><date date-type="accepted"><day>29</day><month>6</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Longatto-Filho et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Longatto-Filho et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Longatto-Filho Adhemar longatto@ecsaude.uminho.pt </dc:author><dc:title> Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>BMC Cancer 9(1): 212-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2407(2009)9:1&#x0003c;212&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2407</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Adenosquamous carcinoma of the uterine cervix is an infrequent but aggressive subtype of cervical cancer. A better understanding of its biological behaviour is warranted to define more accurate prognosis and therapeutic targets. Currently, the blockage of receptor tyrosine kinase (RTKs) activity is an efficient therapeutic strategy for many different cancers. The objective of this study was to investigate EGFR, PDGFRA and VEGFR2 RTKs overexpression and activating gene mutations in a cohort of 30 adenosquamous carcinomas of the uterine cervix.</p></sec><sec sec-type="methods"><title>Methods</title><p>EGFR, PDGFRA and VEGFR2 immunohistochemistry was performed in all samples, followed by DNA isolation from the gross macroscopically dissection of the neoplastic area. Screening for <italic>EGFR </italic>(exons 18&#x02013;21) and <italic>PDGFRA </italic>(exons 12, 14 and 18) mutations was done by PCR &#x02013; single-strand conformational polymorphism (PCR-SSCP).</p></sec><sec><title>Results</title><p>Despite the presence of EGFR immunohistochemical positive reactions in 43% (13/30) of the samples, no <italic>EGFR </italic>activating mutations in the hotspot region (exons 18&#x02013;21) were identified. A silent base substitution (CAG&#x0003e;CAA) in <italic>EGFR </italic>exon 20 at codon 787 (Q787Q) was found in 17 cases (56%). All PDGFRA immunohistochemical reactions were positive and consistently observed in the stromal component, staining fibroblasts and endothelial cells, as well as in the cytoplasm of malignant cells. No activating <italic>PDGFRA </italic>mutations were found, yet, several silent mutations were observed, such as a base substitution in exon 12 (CCA&#x0003e;CCG) at codon 567 (P567P) in 9 cases and in exon 18 (GTC&#x0003e;GTT) at codon 824 (V824V) in 4 cases. We also observed the presence of base substitutions in intron 14 (IVS14+3G&#x0003e;A and IVS14+49G&#x0003e;A) in two different cases, and in intron 18 (IVS18-50insA) in 4 cases. VEGFR2 positivity was observed in 22 of 30 cases (73.3%), and was significantly associated with lack of metastasis (<italic>p </italic>= 0.038).</p></sec><sec><title>Conclusion</title><p>This is the most extensive analysis of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinomas. Despite the absence of <italic>EGFR </italic>and <italic>PDGFRA </italic>activating mutations, the presence of overexpression of these three important therapeutic targets in a subset of cases may be important in predicting the sensitivity of adenosquamous carcinoma to specific anti-RTKs drugs.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Adenosquamous carcinoma (ASC) of the uterine cervix is a relatively infrequent histological subtype of cervical cancer, associated with very aggressive behaviour and reduced survival rates [<xref ref-type="bibr" rid="B1">1</xref>]. ASC histopathological interpretation remains controversial; theoretically, ASC is a mixture of malignant glandular and squamous epithelial elements. However, the practical application of this morphological criterion is far from being straightforward and the prognostic significance of the histological alterations is contentious and does not exactly predict the clinical behaviour of ASC [<xref ref-type="bibr" rid="B2">2</xref>-<xref ref-type="bibr" rid="B4">4</xref>]. The cofactors which contribute to the progression of HPV-infected cervical carcinoma are apparently diverse in each type of histogenetic differentiation. The high risk HPV infection persistence is assumed as a necessary but not sufficient factor to cervical cancer development, and the genetic and molecular disparities involved in the carcinoma progression are still poorly understood [<xref ref-type="bibr" rid="B5">5</xref>]. Therefore, a better understanding of ASC biology is needed to identify the key players and potential novel therapeutic strategies.</p><p>Disruption of the mitogenic signalling mechanisms, particularly the ones mediated by receptor tyrosine kinases (RTKs), is a hallmark of the carcinogenic process and currently constitutes an important therapeutic target group [<xref ref-type="bibr" rid="B6">6</xref>]. RTKs are transmembrane proteins constituted by an extracellular, a transmembrane, a juxtamembrane, and an intracellular domain where two kinase regions are located [<xref ref-type="bibr" rid="B7">7</xref>]. Upon growth factor binding, receptor dimerizes and autophosphorylates its intracellular tyrosine residues that activate several downstream signalling cascades, like MAP kinase, PI3-kinase, and JAK/STAT pathways, affecting cellular gene expression [<xref ref-type="bibr" rid="B8">8</xref>]. In the neoplastic development and progression, RTKS are commonly deregulated, and excessive phosphorylation sustains signal transduction pathways in an activated state, leading to tumour growth and progression, proliferation, dedifferentiation, inhibition of apoptosis, metastasis and angiogenesis [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>]. Among the distinct RTK classes, class I [<italic>e.g</italic>. epidermal growth factor receptor (EGFR)] and class III [<italic>e.g</italic>. platelet-derived growth factor receptor-&#x003b1; (PDGFR-&#x003b1;), KIT, vascular endothelial growth factor receptors 1 (VEGFR1), also known as Flt-1, and VEGFR2 or Flk-1] [<xref ref-type="bibr" rid="B11">11</xref>] have been consistently implicated in solid neoplasm tumourigenesis.</p><p>EGFR was the first RTK to be directly linked to human cancers [<xref ref-type="bibr" rid="B12">12</xref>]. The use of EGFR antagonists, namely monoclonal antibodies directed to the extracellular domain, such as Cetuximab (Erbitux<sup>&#x000ae;</sup>) and small molecule tyrosine kinase inhibitors, such as Gefitinib (Iressa<sup>&#x000ae;</sup>) and Erlotinib (Tarceva<sup>&#x000ae;</sup>), have raised great expectations [<xref ref-type="bibr" rid="B13">13</xref>]. Recently, several molecular alterations have been associated with patient's response to these new anti-EGFR drugs, in particular, <italic>EGFR </italic>mutations in hotspot regions of the intracellular kinase domain (exons 18&#x02013;21) were predictive of a positive response to Gefitinib and Erlotinib in a subset of lung cancer [<xref ref-type="bibr" rid="B11">11</xref>]. Positive therapeutic results have also been reported using KIT and PDGFRA inhibitors such as Imatinib mesylate (Gleevec<sup>&#x000ae;</sup>) for gastrointestinal stromal tumours (GISTs) [<xref ref-type="bibr" rid="B14">14</xref>]. Likewise anti-EGFR drugs, specific gene activating mutations of <italic>KIT </italic>and <italic>PDGFRA </italic>gene seem to predict patients' response to Imatinib [<xref ref-type="bibr" rid="B15">15</xref>]. Besides the use of selective inhibitors, promising therapeutic results are being attained with multi-target inhibitors such as Sunitinib (Sutent<sup>&#x000ae;</sup>), which targets KIT, PDGFR, VEGFR2, Sorafenib (Nexavar<sup>&#x000ae;</sup>) that targets KIT, VEGFR2, PDGFR and intracellular tyrosine kinases, such as BRAF [<xref ref-type="bibr" rid="B14">14</xref>] and Pazopanib, which targets also KIT, PDGFR and VEGFR [<xref ref-type="bibr" rid="B16">16</xref>]. VEGFR2 is not only a mitogenic factor, but essentially an important angiogenic factor; consequently, blocking its activity potentially enhances therapeutic response [<xref ref-type="bibr" rid="B17">17</xref>]. Recently, we reported absence of KIT molecular alterations in ASC and provided evidence for KIT activation through KIT/SCF co-expression in a small proportion of cases [<xref ref-type="bibr" rid="B18">18</xref>], however there are no similar studies with other RTK therapeutic targets.</p><p>The aim of this study was to investigate the presence of EGFR, PDGFRA and VEGFR2 RTKs aberrations, namely overexpression and activating gene mutations in a cohort of 30 adenosquamous carcinomas of the cervix. Accordingly, we intended to assess the potentiality of these RTKs as therapeutic targets in this aggressive tumour type.</p></sec><sec sec-type="methods"><title>Methods</title><sec sec-type="materials"><title>Materials</title><p>This retrospective study comprised a series of 30 patients with ASC of the uterine cervix, examined and treated at two Hospitals, retrieved from the files of Ara&#x000fa;jo Jorge Hospital and from the Pathology Department of the School of Medicine of the Federal University of Goi&#x000e1;s, Goiania, in Goias State, Brazil, from 1986 to 2000. All histopathological diagnoses were revised by two of the authors (FCS, MARM) and categorized according to the WHO classification [<xref ref-type="bibr" rid="B19">19</xref>]. The age of the patients ranged from 24 to 77 years old (mean 49 and median 44.7 years). Clinico-pathological data was available for 29/30 patients and included age at diagnosis, lymph-node and/or distant metastasis, recurrence and overall survival (Table <xref ref-type="table" rid="T1">1</xref>). Of these, 12 patients (41.4%) presented lymph-node and/or distant metastasis and 2 (6.9%) presented disease recurrence. The chosen cut-off for follow-up was 24 months, leaving 20 cases for analysis (mean 38.5 and median 33 months). The present study was approved by the local Ethic Committees.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Clinico-pathological features of ASC patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Case</bold></td><td align="center"><bold>Age</bold></td><td align="center"><bold>Disease recurrence</bold></td><td align="center"><bold>Presence of metastasis*</bold></td><td align="center"><bold>Follow-up (months)</bold></td><td align="center"><bold>Life status</bold></td></tr></thead><tbody><tr><td align="left"><bold>1</bold></td><td align="center">41</td><td align="center">No</td><td align="center">No</td><td align="center">64</td><td align="center">Alive</td></tr><tr><td align="left"><bold>2</bold></td><td align="center">37</td><td align="center">No</td><td align="center">Yes</td><td align="center">22</td><td align="center">Alive</td></tr><tr><td align="left"><bold>3</bold></td><td align="center">55</td><td align="center">NI</td><td align="center">NI</td><td align="center">NI</td><td align="center">NI</td></tr><tr><td align="left"><bold>4</bold></td><td align="center">59</td><td align="center">No</td><td align="center">Yes</td><td align="center">16</td><td align="center">Dead</td></tr><tr><td align="left"><bold>5</bold></td><td align="center">46</td><td align="center">No</td><td align="center">No</td><td align="center">107</td><td align="center">Alive</td></tr><tr><td align="left"><bold>6</bold></td><td align="center">27</td><td align="center">No</td><td align="center">No</td><td align="center">28</td><td align="center">Alive</td></tr><tr><td align="left"><bold>7</bold></td><td align="center">33</td><td align="center">Yes</td><td align="center">No</td><td align="center">36</td><td align="center">Alive</td></tr><tr><td align="left"><bold>8</bold></td><td align="center">67</td><td align="center">No</td><td align="center">No</td><td align="center">34</td><td align="center">Alive</td></tr><tr><td align="left"><bold>9</bold></td><td align="center">40</td><td align="center">No</td><td align="center">No</td><td align="center">35</td><td align="center">Alive</td></tr><tr><td align="left"><bold>10</bold></td><td align="center">54</td><td align="center">No</td><td align="center">Yes</td><td align="center">48</td><td align="center">Dead</td></tr><tr><td align="left"><bold>11</bold></td><td align="center">57</td><td align="center">Yes</td><td align="center">No</td><td align="center">30</td><td align="center">Alive</td></tr><tr><td align="left"><bold>12</bold></td><td align="center">61</td><td align="center">No</td><td align="center">No</td><td align="center">9</td><td align="center">Alive</td></tr><tr><td align="left"><bold>13</bold></td><td align="center">67</td><td align="center">No</td><td align="center">No</td><td align="center">32</td><td align="center">Alive</td></tr><tr><td align="left"><bold>14</bold></td><td align="center">38</td><td align="center">No</td><td align="center">No</td><td align="center">17</td><td align="center">Alive</td></tr><tr><td align="left"><bold>15</bold></td><td align="center">71</td><td align="center">No</td><td align="center">No</td><td align="center">5</td><td align="center">Alive</td></tr><tr><td align="left"><bold>16</bold></td><td align="center">40</td><td align="center">No</td><td align="center">No</td><td align="center">87</td><td align="center">Alive</td></tr><tr><td align="left"><bold>17</bold></td><td align="center">40</td><td align="center">No</td><td align="center">No</td><td align="center">10</td><td align="center">Alive</td></tr><tr><td align="left"><bold>18</bold></td><td align="center">58</td><td align="center">No</td><td align="center">Yes</td><td align="center">47</td><td align="center">Dead</td></tr><tr><td align="left"><bold>19</bold></td><td align="center">47</td><td align="center">No</td><td align="center">No</td><td align="center">22</td><td align="center">Alive</td></tr><tr><td align="left"><bold>20</bold></td><td align="center">41</td><td align="center">No</td><td align="center">No</td><td align="center">14</td><td align="center">Alive</td></tr><tr><td align="left"><bold>21</bold></td><td align="center">39</td><td align="center">No</td><td align="center">Yes</td><td align="center">9</td><td align="center">Dead</td></tr><tr><td align="left"><bold>22</bold></td><td align="center">40</td><td align="center">No</td><td align="center">Yes</td><td align="center">48</td><td align="center">Alive</td></tr><tr><td align="left"><bold>23</bold></td><td align="center">45</td><td align="center">No</td><td align="center">No</td><td align="center">35</td><td align="center">Alive</td></tr><tr><td align="left"><bold>24</bold></td><td align="center">53</td><td align="center">No</td><td align="center">Yes</td><td align="center">13</td><td align="center">Alive</td></tr><tr><td align="left"><bold>25</bold></td><td align="center">29</td><td align="center">No</td><td align="center">Yes</td><td align="center">14</td><td align="center">Dead</td></tr><tr><td align="left"><bold>26</bold></td><td align="center">36</td><td align="center">No</td><td align="center">Yes</td><td align="center">19</td><td align="center">Dead</td></tr><tr><td align="left"><bold>27</bold></td><td align="center">24</td><td align="center">No</td><td align="center">Yes</td><td align="center">6</td><td align="center">Alive</td></tr><tr><td align="left"><bold>28</bold></td><td align="center">48</td><td align="center">No</td><td align="center">Yes</td><td align="center">NI</td><td align="center">Dead</td></tr><tr><td align="left"><bold>29</bold></td><td align="center">56</td><td align="center">No</td><td align="center">No</td><td align="center">22</td><td align="center">Alive</td></tr><tr><td align="left"><bold>30</bold></td><td align="center">77</td><td align="center">No</td><td align="center">Yes</td><td align="center">17</td><td align="center">Alive</td></tr></tbody></table><table-wrap-foot><p>* Lymph-node and/or distant metastasis; NI, no information available.</p></table-wrap-foot></table-wrap></sec><sec><title>EGFR, PDGFRA and VEGFR2 Immunohistochemistry</title><p>EGFR immunohistochemistry analysis of the present series was previously assessed [<xref ref-type="bibr" rid="B20">20</xref>]. For PDGFRA and VEGFR2 expression, immunohistochemistry procedure was performed according to streptavidin-biotin-peroxidase complex principle, using specific antibodies raised against PDGFRA (dilution 1:175, Clone C-20, Santa Cruz Biotechnology, CA), and VEGFR2 (dilution 1:50, Neomarkers, LabVision Corporation, Fremont, CA), as previously described [<xref ref-type="bibr" rid="B21">21</xref>-<xref ref-type="bibr" rid="B23">23</xref>]. In brief, deparaffinised and rehydrated sections were pre-treated by microwaving in 10 mM citrate buffer (pH 6.0) three times for 5 minutes at 600W. After incubation of VEGFR2 (overnight at 4&#x000b0;C) and PDGFRA (30 minutes at room temperature) primary antibody, the secondary biotinylated goat anti-polyvalent antibody was applied for 10 minutes, followed by incubation with streptavidin-peroxidase complex. The immune reaction was visualised by DAB as a chromogen (Ultravision Detection System Anti-polyvalent, HRP/DAB; LabVision Corporation, Fremont, CA). Appropriated positive and negative controls were included in each run: for PDGFRA, cutaneous-mucosa transition of the anal region, namely medium calibre vessels with a muscular layer was used as positive controls; an angiosarcoma tissue with immunostaining of the blood vessels was used for VEGFR2. For negative controls, primary antibodies were omitted and also replaced by a universal negative control antibody (CEA, rabbit anti-human, DAKO Corporation, Carpinteria, CA). All sections were counterstained with Gill-2 haematoxylin. The immunohistochemical reactions were evaluated as described previously [<xref ref-type="bibr" rid="B21">21</xref>]. Briefly, sections were semi-quantitatively scored as follows: (-), 0% of immunoreactive cells; (+), &#x0003c;5% of immunoreactive cells; (++), 5&#x02013;50% of immunoreactive cells; and (+++), &#x0003e;50% of immunoreactive cells. Samples with scores (-) and (+) were considered negative, and those with scores (++) and (+++) were considered positive.</p></sec><sec><title>DNA isolation</title><p>Serial 10 &#x003bc;m unstained sections of paraffin blocks were cut, and one adjacent hematoxylin and eosin-stained section was taken for identification and selection of the tumour tissue. Selected areas containing at least 85% of tumour were marked and, using a sterile needle (Neolus, 25 G-0.5 mm), gross macroscopically dissection was performed. Tissue was placed into a microfuge tube and DNA isolation was performed using Qiagen's QIAamp<sup>&#x000ae; </sup>DNA Micro Kit (Qiagen, Hilden, Germany), as previously described [<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B24">24</xref>].</p></sec><sec><title>Screening for <italic>EGFR </italic>and <italic>PDGFRA </italic>Mutations</title><p>Screening for <italic>EGFR </italic>(exons 18&#x02013;21) and <italic>PDGFRA </italic>(exons 12, 14 and 18) mutations was done by PCR &#x02013; single-strand conformational polymorphism (PCR-SSCP), as previously described [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B25">25</xref>]. Samples showing a mobility shift different from the normal pattern were directly sequenced (Stabvida, Investigation and Services in Biological Sciences Lda, Oeiras, Portugal), as described [<xref ref-type="bibr" rid="B25">25</xref>]. All positive cases were confirmed twice with a new and independent PCR amplification, followed by direct sequencing.</p></sec><sec><title>Statistical analysis</title><p>Data were stored and analyzed using the SPSS statistical software (version 16.0, SPSS Inc., Chicago, IL). All comparisons were examined for statistical significance using Pearson's chi-square (&#x003c7;<sup>2</sup>) test and Fisher's exact test (when n &#x0003c; 5), being threshold for significance <italic>p </italic>values &#x0003c; 0.05. Survival curve was plotted using the method of Kaplan and Meier and data compared using the log-rank test.</p></sec></sec><sec><title>Results</title><p>Assessment of EGFR, PDGFRA and VEGFR2 overexpression and activating gene mutations was performed in a cohort of 30 adenosquamous carcinomas of the uterine cervix. The results are summarized in Table <xref ref-type="table" rid="T2">2</xref> and are detailed bellow.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Molecular alterations of EGFR, PDGFRA and VEGFR2 in ASC patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Case</bold></td><td align="center" colspan="2"><bold>EGFR</bold></td><td align="center" colspan="2"><bold>PDGFRA</bold></td><td align="center"><bold>VEGFR2</bold></td></tr><tr><td></td><td colspan="2"><hr></hr></td><td colspan="2"><hr></hr></td><td colspan="1"><hr></hr></td></tr><tr><td></td><td align="center"><bold>Mutations</bold></td><td align="center"><bold>IHC*</bold></td><td align="center"><bold>Mutations</bold></td><td align="center"><bold>IHC</bold></td><td align="center"><bold>IHC</bold></td></tr></thead><tbody><tr><td align="left"><bold>1</bold></td><td align="center">Q787Q</td><td align="center">-</td><td align="center">P567P; V824V; IVS18-50insA</td><td align="center">+++</td><td align="center">++</td></tr><tr><td align="left"><bold>2</bold></td><td align="center">Normal</td><td align="center">+++</td><td align="center">Normal</td><td align="center">+++</td><td align="center">-</td></tr><tr><td align="left"><bold>3</bold></td><td align="center">Q787Q</td><td align="center">+++</td><td align="center">V824V; IVS18-50insA</td><td align="center">+++</td><td align="center">+++</td></tr><tr><td align="left"><bold>4</bold></td><td align="center">Q787Q</td><td align="center">+++</td><td align="center">V824V; IVS18-50insA</td><td align="center">+++</td><td align="center">+++</td></tr><tr><td align="left"><bold>5</bold></td><td align="center">Q787Q</td><td align="center">+++</td><td align="center">V824V; IVS18-50insA</td><td align="center">+++</td><td align="center">+++</td></tr><tr><td align="left"><bold>6</bold></td><td align="center">Normal</td><td align="center">+</td><td align="center">Normal</td><td align="center">+++</td><td align="center">+++</td></tr><tr><td align="left"><bold>7</bold></td><td align="center">Q787Q</td><td align="center">+++</td><td align="center">P567P; IVS14+3G&#x0003e;A</td><td align="center">+++</td><td align="center">++</td></tr><tr><td align="left"><bold>8</bold></td><td align="center">Q787Q</td><td align="center">-</td><td align="center">Normal</td><td align="center">+++</td><td align="center">+++</td></tr><tr><td align="left"><bold>9</bold></td><td align="center">Normal</td><td align="center">-</td><td align="center">Normal</td><td align="center">+++</td><td align="center">+++</td></tr><tr><td align="left"><bold>10</bold></td><td align="center">Normal</td><td align="center">+++</td><td align="center">P567P</td><td align="center">+++</td><td align="center">+++</td></tr><tr><td align="left"><bold>11</bold></td><td align="center">Normal</td><td align="center">-</td><td align="center">P567P</td><td align="center">np</td><td align="center">+++</td></tr><tr><td align="left"><bold>12</bold></td><td align="center">Q787Q</td><td align="center">-</td><td align="center">Normal</td><td align="center">+++</td><td align="center">+++</td></tr><tr><td align="left"><bold>13</bold></td><td align="center">Q787Q</td><td align="center">-</td><td align="center">Normal</td><td align="center">++</td><td align="center">+++</td></tr><tr><td align="left"><bold>14</bold></td><td align="center">Normal</td><td align="center">++</td><td align="center">Normal</td><td align="center">+++</td><td align="center">++</td></tr><tr><td align="left"><bold>15</bold></td><td align="center">Q787Q</td><td align="center">+</td><td align="center">Normal</td><td align="center">+++</td><td align="center">+++</td></tr><tr><td align="left"><bold>16</bold></td><td align="center">Normal</td><td align="center">+++</td><td align="center">P567P</td><td align="center">+++</td><td align="center">+</td></tr><tr><td align="left"><bold>17</bold></td><td align="center">Q787Q</td><td align="center">-</td><td align="center">P567P</td><td align="center">++</td><td align="center">+++</td></tr><tr><td align="left"><bold>18</bold></td><td align="center">Normal</td><td align="center">-</td><td align="center">Normal</td><td align="center">+++</td><td align="center">+</td></tr><tr><td align="left"><bold>19</bold></td><td align="center">Q787Q</td><td align="center">+++</td><td align="center">Normal</td><td align="center">+++</td><td align="center">++</td></tr><tr><td align="left"><bold>20</bold></td><td align="center">Q787Q</td><td align="center">-</td><td align="center">Normal</td><td align="center">+++</td><td align="center">+++</td></tr><tr><td align="left"><bold>21</bold></td><td align="center">Normal</td><td align="center">+</td><td align="center">P567P</td><td align="center">np</td><td align="center">+++</td></tr><tr><td align="left"><bold>22</bold></td><td align="center">Normal</td><td align="center">++</td><td align="center">P567P</td><td align="center">+++</td><td align="center">+</td></tr><tr><td align="left"><bold>23</bold></td><td align="center">Normal</td><td align="center">+++</td><td align="center">Normal</td><td align="center">++</td><td align="center">++</td></tr><tr><td align="left"><bold>24</bold></td><td align="center">Q787Q</td><td align="center">-</td><td align="center">Normal</td><td align="center">++</td><td align="center">+</td></tr><tr><td align="left"><bold>25</bold></td><td align="center">Q787Q</td><td align="center">+</td><td align="center">IVS14+49G&#x0003e;A</td><td align="center">+++</td><td align="center">+</td></tr><tr><td align="left"><bold>26</bold></td><td align="center">Q787Q</td><td align="center">-</td><td align="center">P567P</td><td align="center">+++</td><td align="center">+++</td></tr><tr><td align="left"><bold>27</bold></td><td align="center">Normal</td><td align="center">-</td><td align="center">Normal</td><td align="center">np</td><td align="center">++</td></tr><tr><td align="left"><bold>28</bold></td><td align="center">Q787Q</td><td align="center">++</td><td align="center">Normal</td><td align="center">++</td><td align="center">+</td></tr><tr><td align="left"><bold>29</bold></td><td align="center">Q787Q</td><td align="center">-</td><td align="center">Normal</td><td align="center">+++</td><td align="center">+</td></tr><tr><td align="left"><bold>30</bold></td><td align="center">Normal</td><td align="center">+++</td><td align="center">Normal</td><td align="center">++</td><td align="center">+++</td></tr></tbody></table><table-wrap-foot><p>IHC: Immunohistochemistry; *: previously reported in [<xref ref-type="bibr" rid="B20">20</xref>]; np: not possible due to tissue limitation.</p></table-wrap-foot></table-wrap><sec><title>EGFR profile</title><p>We have previously found that approximately 43% (13/30) of cases were positive (2+/3+) for EGFR immunohistochemistry (Figure <xref ref-type="fig" rid="F1">1A</xref>) [<xref ref-type="bibr" rid="B20">20</xref>]. In order to determine the molecular basis of such overexpression, we have performed a mutation analysis of cases. No activating mutations in the hotspot region (exons 18&#x02013;21) of <italic>EGFR </italic>gene were identified. Nevertheless, a silent base substitution (CAG&#x0003e;CAA) in <italic>EGFR </italic>exon 20 at codon 787 (Q787Q) was found in 17 cases (56%) (Table <xref ref-type="table" rid="T3">3</xref>).</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Sequence variants of <italic>EGFR </italic>and <italic>PDGFRA </italic>gene in ASC patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Gene (exon)</bold></td><td align="left"><bold>Nucleotide Change</bold></td><td align="center"><bold>Aminoacid Substitution</bold></td><td align="center"><bold>N&#x000b0; of cases</bold></td><td align="left"><bold>dbSNP</bold></td></tr></thead><tbody><tr><td align="left"><bold><italic>EGFR </italic>(exon 20)</bold></td><td align="left">2361 G&#x0003e;A</td><td align="center">Q787Q</td><td align="center">17</td><td align="left">rs1050171</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left"><bold><italic>PDGFRA </italic>(exon 12)</bold></td><td align="left">1701 G&#x0003e;A</td><td align="center">P567P</td><td align="center">9</td><td align="left">rs1873778</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left"><bold><italic>PDGFRA </italic>(exon 14)</bold></td><td align="left">2002+3G&#x0003e;A</td><td align="center">IVS14+3G&#x0003e;A</td><td align="center">1</td><td align="left">Not yet described</td></tr><tr><td></td><td align="left">2002+49G&#x0003e;A</td><td align="center">IVS14+49G&#x0003e;A</td><td align="center">1</td><td align="left">Not yet described</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left"><bold><italic>PDGFRA </italic>(exon 18)</bold></td><td align="left">2472 C&#x0003e;T</td><td align="center">V824V</td><td align="center">4</td><td align="left">rs2228230</td></tr><tr><td></td><td align="left">2449-50insA</td><td align="center">IVS18-50insA</td><td align="center">4</td><td align="left">rs3830355</td></tr></tbody></table><table-wrap-foot><p>dbSNP: Single Nucleotide Polymorphism database <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/"/></p></table-wrap-foot></table-wrap><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Immunohistochemical expression of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma</bold>. <bold>A) </bold>EGFR positive immunoreaction decorating the cytoplasm of malignant cells. No stromal or endothelial positive reactions were observed (original magnification &#x000d7;40). <bold>B) </bold>PDGFRA positive immunoreaction was observed in the cytoplasm of malignant cells. PDGFRA positive reaction was also constantly observed in the stromal component, decorating fibroblasts and endothelial cells (original magnification &#x000d7;40). <bold>C) </bold>VEGFR2 positive immunoreaction was in the cytoplasm of malignant cells. No stromal positive reaction was identified, but positive staining was observed in a few endothelial cells surrounding the neoplastic cells (original magnification &#x000d7;40).</p></caption><graphic xlink:href="1471-2407-9-212-1"/></fig><p>No statistically significant correlations were observed between <italic>EGFR </italic>gene alteration and the clinico-pathological parameters (data not shown).</p></sec><sec><title>PDGFRA profile</title><p>PDGFRA immunohistochemical analysis was only possible in 27 out of 30 cases, all of them being positive for PDGFRA expression. Six cases showed moderate positivity (2+) and 21 showed strong positivity (3+) (Figure <xref ref-type="fig" rid="F1">1B</xref>). Positive immunoreactions were observed in the cytoplasm of malignant cells, and were consistently observed in the stromal component, staining fibroblasts and endothelial cells.</p><p>Mutation analysis of <italic>PDGFRA </italic>hotspot exons 12, 14 and 18 of all 30 cases, revealed absence of activating mutations. Yet, we observed several silent mutations, such as a base substitution in exon 12 (CCA&#x0003e;CCG) at codon 567 (P567P) in 9 cases and in exon 18 (GTC&#x0003e;GTT) at codon 824 (V824V) in 4 cases (Table <xref ref-type="table" rid="T2">2</xref>). We also observed base substitutions in intron 14 (IVS14+3G&#x0003e;A and IVS14+49G&#x0003e;A) (Figure <xref ref-type="fig" rid="F2">2</xref>), in two different cases, and in intron 18 (IVS18-50insA) in 4 cases (Table <xref ref-type="table" rid="T3">3</xref>).</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>Electropherogram of part of <italic>PDGFRA </italic>sequence</bold>. DNA sequencing of an intronic base substitution (IVS14+49G&#x0003e;A) in <italic>PDGFRA </italic>intron 14. Arrow indicates G to A transition at 2002 base pairs.</p></caption><graphic xlink:href="1471-2407-9-212-2"/></fig><p>Since all cases were positive for PDGFRA expression, analysis of correlations with the clinico-pathological data was not performed.</p></sec><sec><title>VEGFR2 profile</title><p>VEGFR2 immunohistochemical positivity was observed in 22 of 30 cases (73.3%), with 6 cases showing moderate expression (2+) and 16 cases presenting strong positive immunoreaction (3+). Positive immunoreactions were exclusively observed in the cytoplasm of malignant cells. No stromal positive reaction was identified, but faint positive staining was observed in a few endothelial cells surrounding the neoplastic cells (Figure <xref ref-type="fig" rid="F1">1C</xref>).</p><p>Correlation analysis between VEGFR2 expression and clinico-pathological data revealed a significant association between VEGFR2 overexpression and lack of metastasis (<italic>p </italic>= 0.038). No associations between VEGFR2 expression and overall survival and disease recurrence were found (data not shown).</p></sec></sec><sec><title>Discussion</title><p>Advances in the knowledge of the altered molecular events in neoplastic cells have paved the way to the discovery of new and promising targets and drugs for cancer treatment. Three of these potential targets are EGFR, PDGFR and VEGFR2, which have important roles in tumour proliferation and angiogenesis. The results herein reported aimed to identify molecular alterations in these therapeutic targets predictive of a positive response to selective inhibitors in cervical adenosquamous carcinoma (ASC).</p><p>Overexpression of EGFR has been reported to be frequent in cervical cancer, ranging from approximately 25&#x02013;70% [<xref ref-type="bibr" rid="B26">26</xref>-<xref ref-type="bibr" rid="B31">31</xref>]. Most studies have focused the analysis squamous cell carcinomas [<xref ref-type="bibr" rid="B26">26</xref>-<xref ref-type="bibr" rid="B31">31</xref>]. We and others have shown that in adenosquamous carcinoma EGFR overexpression varies from 33&#x02013;43% of cases, being in the range of overall cervical cancer [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B29">29</xref>]. Despite the presence of EGFR overexpression, we showed that none of adenosquamous carcinomas harbour <italic>EGFR </italic>gene activating mutations. Nevertheless, a silent base substitution (CAG&#x0003e;CAA) in EGFR exon 20 at codon 787 (Q787Q) was found in 17 cases (56%). This polymorphism is a known single nucleotide polymorphism (SNP), which frequencies vary in different populations, being the G allele more frequent in Asians and African Americans, whereas the A allele is more frequent in Europeans (rs1050171, NCBI SNP database). The implication of this SNP in EGFR function is still unclear. Taguchi <italic>et al</italic>, analysing head and neck squamous cell carcinomas did not observe any significant differences at EGFR mRNA and protein levels in cell lines harbouring different genotypes, despite the described higher sensitivity of (G/A) heterozygous when compared with (G/G) homozygous cell lines to Gefitinib [<xref ref-type="bibr" rid="B32">32</xref>]. Recently, Arias-Pulido <italic>et al</italic>, also described the absence of <italic>EGFR </italic>activating mutations in a large series of 89 cervical cancers, including 75 squamous cell carcinomas and 5 adenocarcinomas [<xref ref-type="bibr" rid="B33">33</xref>]. The mechanism driving EGFR overexpression in adenosquamous carcinomas remains to be determined. Previous studies have shown that EGFR could be regulated by <italic>EGFR </italic>gene amplification [<xref ref-type="bibr" rid="B28">28</xref>] or by HPV oncoproteins, namely the HPV E5 and E6, which are linked with increased EGFR levels, through inhibition of EGFR internalization and degradation [<xref ref-type="bibr" rid="B34">34</xref>,<xref ref-type="bibr" rid="B35">35</xref>].</p><p>Several clinical trials are evaluating the efficacy of anti-EGFR therapies for advanced cervical cancer [<xref ref-type="bibr" rid="B6">6</xref>]. Studies of cetuximab-based therapy, either in monotherapy or in association with radiotherapy are ongoing for treatment of recurrent and early cervical carcinoma [Gynecologic Oncology Group (GOG)-0227E; GOG-9918]. A multicenter phase II trial evaluated the clinical outcomes of Gefitinib-based therapy in 30 patients with recurring loco regionally advanced or metastatic cervical cancer [<xref ref-type="bibr" rid="B36">36</xref>]. There were no objective responses, however, 1/5 of patients exhibited stable disease, and tumour response was not correlated with EGFR immunohistochemistry levels [<xref ref-type="bibr" rid="B36">36</xref>]. These results are not surprising, since it is known that in cancer patients, particularly those with lung cancer, it is the presence of <italic>EGFR </italic>tyrosine kinase activating mutations rather than EGFR immunoreactivity that is associated with a marked clinical response [<xref ref-type="bibr" rid="B37">37</xref>]. Since our results indicate the absence of <italic>EGFR </italic>activating mutations in ASC, we would predict that Gefitinib, as well as Erlotinib, in monotherapy are unlikely to be effective in these patients.</p><p>Very few studies addressed the role of PDGFRA in cervical carcinogenesis [<xref ref-type="bibr" rid="B38">38</xref>-<xref ref-type="bibr" rid="B40">40</xref>]. Taja-Chayeb <italic>et al</italic>, have analyzed a total of 36 cases, which included 4 adenosquamous carcinomas. The authors reported overexpression of PDGFRA in neoplastic cells in approximately 42% cases, and a less frequent overexpression in stromal cells (~8%) [<xref ref-type="bibr" rid="B38">38</xref>]. In a recent and elegant study, Pietras K <italic>et al</italic>, showed that PDGFRA is almost ubiquitously expressed in the stroma of cervical cancers, but is much less expressed in neoplastic cells [<xref ref-type="bibr" rid="B40">40</xref>]. In the present study, we detected PDGFRA overexpression in all cases, either in the neoplastic or stromal component of tumours. These discrepancies could be due in part to the different antibodies used and to distinct histological subtypes analysed. In the present study, no activating mutations were observed, regardless of the presence of several genetic variants, many of them being known as genetic polymorphisms. Our results are in agreement with the described absence of activating mutations in 17 cervical carcinomas [<xref ref-type="bibr" rid="B38">38</xref>]. Nevertheless, recent preclinical studies in mouse model and human cervical carcinomas tumour samples, showed significant therapeutic benefits of Imatinib-based therapy [<xref ref-type="bibr" rid="B40">40</xref>,<xref ref-type="bibr" rid="B41">41</xref>].</p><p>VEGFR2 is widely distributed in human tissues and tumours [<xref ref-type="bibr" rid="B42">42</xref>]. These receptors were originally thought to be only present in activated endothelial cells; however, recent immunohistochemical studies showed that VEGFR2 is also present in cancer cells and that translocation of phosphorylated VEGFR2 to the nuclei is a frequent event presumably being linked to an existing autocrine VEGF/VEGFR2 loop [<xref ref-type="bibr" rid="B42">42</xref>-<xref ref-type="bibr" rid="B44">44</xref>]. An interesting recent report suggests that VEGFR2 is a marker of precancerous stem cells [<xref ref-type="bibr" rid="B45">45</xref>]. To the best of our knowledge, there are no reports on VEGFR2 expression in cervical adenosquamous carcinomas. We showed presence of neoplastic VEGFR2 expression in approximately 2/3 of cases. Our data showed an association between VEGFR2 overexpression and lack of metastasis. This apparently paradox may suggest that other alternative molecules can drive the metastatic spread in this rare type of cervical cancer, even when VEGFR2 is overexpressed in the cancer cell cytoplasm, as observed in the present study. Several clinical trials of anti-VEGFR2 drugs are being conducted in cervical cancer [<xref ref-type="bibr" rid="B6">6</xref>]. Sorafenib, is being assessed in a phase I/II clinical trial in combination with radiotherapy and cisplatin (DDPDRO-002) [<xref ref-type="bibr" rid="B46">46</xref>]. Presently, simultaneous inhibition of several receptors tyrosine kinases is believed to optimize the overall therapeutic benefit associated with molecular targeted anticancer agents [<xref ref-type="bibr" rid="B47">47</xref>]. A clinical study is ongoing to evaluate the efficacy and safety of Pazopanib and Lapatinib, a dual tyrosine kinase inhibitor of EGFR and HER2, alone or in combination in patients with metastatic cervical cancer (VEG105281) [<xref ref-type="bibr" rid="B48">48</xref>].</p></sec><sec><title>Conclusion</title><p>In conclusion, the present study is most the comprehensive analysis of EGFR, PDGFRA and VEGFR2 oncogenes in adenosquamous carcinoma. We observed absence of activating mutations in <italic>EGFR </italic>and <italic>PDGFRA </italic>oncogenes, despite the presence of protein overexpression. VEGR2 was frequently overexpressed and associated with lack of metastasis. The current molecular profiling can be valuable for future selection of adenosquamous cervical carcinoma therapeutic options.</p></sec><sec><title>Authors' contributions</title><p>ALF and RMR were responsible for study concept and design, study supervision, and manuscript drafting and critical revision. CP, OM and FB performed the molecular genetic studies, immunohistochemistry reactions and participated in the drafting of the manuscript. MARM, LFJR and GSQ were responsible for clinico-pathological collection and drafting of the manuscript. FCS and ALF assessed immunohistochemistry results and drafting of the manuscript. All the authors read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/9/212/prepub"/></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>CP and OM are recipients of PhD fellowships from the Portuguese Science and Technology Foundation (FCT) (SFRH/BD/27465/2006 and SFRH/BD/36463/2007, respectively).</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Castellsague</surname><given-names>X</given-names></name><name><surname>Diaz</surname><given-names>M</given-names></name><name><surname>de</surname><given-names>SS</given-names></name><name><surname>Munoz</surname><given-names>N</given-names></name><name><surname>Herrero</surname><given-names>R</given-names></name><name><surname>Franceschi</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention</article-title><source>J Natl Cancer Inst</source><year>2006</year><volume>98</volume><fpage>303</fpage><lpage>315</lpage><pub-id pub-id-type="pmid">16507827</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chao</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>TH</given-names></name><name><surname>Lee</surname><given-names>YS</given-names></name><name><surname>Hsueh</surname><given-names>S</given-names></name><name><surname>Chao</surname><given-names>AS</given-names></name><name><surname>Chang</surname><given-names>TC</given-names></name><etal></etal></person-group><article-title>Molecular characterization of adenocarcinoma and squamous carcinoma of the uterine cervix using microarray analysis of gene expression</article-title><source>Int J Cancer</source><year>2006</year><volume>119</volume><fpage>91</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">16450401</pub-id><pub-id pub-id-type="doi">10.1002/ijc.21813</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Farley</surname><given-names>JH</given-names></name><name><surname>Hickey</surname><given-names>KW</given-names></name><name><surname>Carlson</surname><given-names>JW</given-names></name><name><surname>Rose</surname><given-names>GS</given-names></name><name><surname>Kost</surname><given-names>ER</given-names></name><name><surname>Harrison</surname><given-names>TA</given-names></name></person-group><article-title>Adenosquamous histology predicts a poor outcome for patients with advanced-stage, but not early-stage, cervical carcinoma</article-title><source>Cancer</source><year>2003</year><volume>97</volume><fpage>2196</fpage><lpage>2202</lpage><pub-id pub-id-type="pmid">12712471</pub-id><pub-id pub-id-type="doi">10.1002/cncr.11371</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lea</surname><given-names>JS</given-names></name><name><surname>Coleman</surname><given-names>RL</given-names></name><name><surname>Garner</surname><given-names>EO</given-names></name><name><surname>Duska</surname><given-names>LR</given-names></name><name><surname>Miller</surname><given-names>DS</given-names></name><name><surname>Schorge</surname><given-names>JO</given-names></name></person-group><article-title>Adenosquamous histology predicts poor outcome in low-risk stage IB1 cervical adenocarcinoma</article-title><source>Gynecol Oncol</source><year>2003</year><volume>91</volume><fpage>558</fpage><lpage>562</lpage><pub-id pub-id-type="pmid">14675676</pub-id><pub-id pub-id-type="doi">10.1016/j.ygyno.2003.08.020</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dellas</surname><given-names>A</given-names></name><name><surname>Torhorst</surname><given-names>J</given-names></name><name><surname>Gaudenz</surname><given-names>R</given-names></name><name><surname>Mihatsch</surname><given-names>MJ</given-names></name><name><surname>Moch</surname><given-names>H</given-names></name></person-group><article-title>DNA copy number changes in cervical adenocarcinoma</article-title><source>Clin Cancer Res</source><year>2003</year><volume>9</volume><fpage>2985</fpage><lpage>2991</lpage><pub-id pub-id-type="pmid">12912946</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Del Campo</surname><given-names>JM</given-names></name><name><surname>Prat</surname><given-names>A</given-names></name><name><surname>Gil-Moreno</surname><given-names>A</given-names></name><name><surname>Perez</surname><given-names>J</given-names></name><name><surname>Parera</surname><given-names>M</given-names></name></person-group><article-title>Update on novel therapeutic agents for cervical cancer</article-title><source>Gynecol Oncol</source><year>2008</year><volume>110</volume><fpage>S72</fpage><lpage>S76</lpage><pub-id pub-id-type="pmid">18544460</pub-id><pub-id pub-id-type="doi">10.1016/j.ygyno.2008.04.016</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perona</surname><given-names>R</given-names></name></person-group><article-title>Cell signalling: growth factors and tyrosine kinase receptors</article-title><source>Clin Transl Oncol</source><year>2006</year><volume>8</volume><fpage>77</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">16632420</pub-id><pub-id pub-id-type="doi">10.1007/s12094-006-0162-1</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kitamura</surname><given-names>Y</given-names></name><name><surname>Hirotab</surname><given-names>S</given-names></name></person-group><article-title>Kit as a human oncogenic tyrosine kinase</article-title><source>Cell Mol Life Sci</source><year>2004</year><volume>61</volume><fpage>2924</fpage><lpage>2931</lpage><pub-id pub-id-type="pmid">15583854</pub-id><pub-id pub-id-type="doi">10.1007/s00018-004-4273-y</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blume-Jensen</surname><given-names>P</given-names></name><name><surname>Hunter</surname><given-names>T</given-names></name></person-group><article-title>Oncogenic kinase signalling</article-title><source>Nature</source><year>2001</year><volume>411</volume><fpage>355</fpage><lpage>365</lpage><pub-id pub-id-type="pmid">11357143</pub-id><pub-id pub-id-type="doi">10.1038/35077225</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Raymond</surname><given-names>E</given-names></name><name><surname>Faivre</surname><given-names>S</given-names></name><name><surname>Armand</surname><given-names>JP</given-names></name></person-group><article-title>Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy</article-title><source>Drugs</source><year>2000</year><volume>60</volume><fpage>15</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">11129168</pub-id><pub-id pub-id-type="doi">10.2165/00003495-200060001-00002</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Press</surname><given-names>MF</given-names></name><name><surname>Lenz</surname><given-names>HJ</given-names></name></person-group><article-title>EGFR, HER2 and VEGF pathways: validated targets for cancer treatment</article-title><source>Drugs</source><year>2007</year><volume>67</volume><fpage>2045</fpage><lpage>2075</lpage><pub-id pub-id-type="pmid">17883287</pub-id><pub-id pub-id-type="doi">10.2165/00003495-200767140-00006</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yarden</surname><given-names>Y</given-names></name><name><surname>Schlessinger</surname><given-names>J</given-names></name></person-group><article-title>Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor</article-title><source>Biochemistry</source><year>1987</year><volume>26</volume><fpage>1443</fpage><lpage>1451</lpage><pub-id pub-id-type="pmid">3494473</pub-id><pub-id pub-id-type="doi">10.1021/bi00379a035</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tomillero</surname><given-names>A</given-names></name><name><surname>Moral</surname><given-names>MA</given-names></name></person-group><article-title>Gateways to clinical trials</article-title><source>Methods Find Exp Clin Pharmacol</source><year>2008</year><volume>30</volume><fpage>543</fpage><lpage>588</lpage><pub-id pub-id-type="pmid">18985183</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kitamura</surname><given-names>Y</given-names></name></person-group><article-title>Gastrointestinal stromal tumors: past, present, and future</article-title><source>J Gastroenterol</source><year>2008</year><volume>43</volume><fpage>499</fpage><lpage>508</lpage><pub-id pub-id-type="pmid">18648736</pub-id><pub-id pub-id-type="doi">10.1007/s00535-008-2200-y</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>S</given-names></name><name><surname>Alexiadis</surname><given-names>M</given-names></name><name><surname>Fuller</surname><given-names>PJ</given-names></name></person-group><article-title>Expression, mutational analysis and in vitro response of imatinib mesylate and nilotinib target genes in ovarian granulosa cell tumors</article-title><source>Gynecol Oncol</source><year>2008</year><volume>108</volume><fpage>182</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">18028988</pub-id><pub-id pub-id-type="doi">10.1016/j.ygyno.2007.09.017</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sloan</surname><given-names>B</given-names></name><name><surname>Scheinfeld</surname><given-names>NS</given-names></name></person-group><article-title>Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy</article-title><source>Curr Opin Investig Drugs</source><year>2008</year><volume>9</volume><fpage>1324</fpage><lpage>1335</lpage><pub-id pub-id-type="pmid">19037839</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schenone</surname><given-names>S</given-names></name><name><surname>Bondavalli</surname><given-names>F</given-names></name><name><surname>Botta</surname><given-names>M</given-names></name></person-group><article-title>Antiangiogenic agents: an update on small molecule VEGFR inhibitors</article-title><source>Curr Med Chem</source><year>2007</year><volume>14</volume><fpage>2495</fpage><lpage>2516</lpage><pub-id pub-id-type="pmid">17979703</pub-id><pub-id pub-id-type="doi">10.2174/092986707782023622</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martinho</surname><given-names>O</given-names></name><name><surname>Goncalves</surname><given-names>A</given-names></name><name><surname>Moreira</surname><given-names>MA</given-names></name><name><surname>Ribeiro</surname><given-names>LF</given-names></name><name><surname>Queiroz</surname><given-names>GS</given-names></name><name><surname>Schmitt</surname><given-names>FC</given-names></name><etal></etal></person-group><article-title>KIT activation in uterine cervix adenosquamous carcinomas by KIT/SCF autocrine/paracrine stimulation loops</article-title><source>Gynecol Oncol</source><year>2008</year><volume>111</volume><fpage>350</fpage><lpage>355</lpage><pub-id pub-id-type="pmid">18708242</pub-id><pub-id pub-id-type="doi">10.1016/j.ygyno.2008.07.011</pub-id></citation></ref><ref id="B19"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Tavassoli</surname><given-names>FA</given-names></name><name><surname>Devilee</surname><given-names>P</given-names></name></person-group><source>WHO Classification of Tumours: Pathology and Genetics of Tumours of the Breast and Female Genital Organs</source><year>2003</year><publisher-name>Lyon: IARC Press</publisher-name></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baltazar</surname><given-names>F</given-names></name><name><surname>Filho</surname><given-names>AL</given-names></name><name><surname>Pinheiro</surname><given-names>C</given-names></name><name><surname>Moreira</surname><given-names>MA</given-names></name><name><surname>Queiroz</surname><given-names>GS</given-names></name><name><surname>Oton</surname><given-names>GJ</given-names></name><etal></etal></person-group><article-title>Cyclooxygenase-2 and epidermal growth factor receptor expressions in different histological subtypes of cervical carcinomas</article-title><source>Int J Gynecol Pathol</source><year>2007</year><volume>26</volume><fpage>235</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">17581404</pub-id><pub-id pub-id-type="doi">10.1097/pgp.0b013e31802f1996</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reis-Filho</surname><given-names>JS</given-names></name><name><surname>Pinheiro</surname><given-names>C</given-names></name><name><surname>Lambros</surname><given-names>MB</given-names></name><name><surname>Milanezi</surname><given-names>F</given-names></name><name><surname>Carvalho</surname><given-names>S</given-names></name><name><surname>Savage</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>EGFR amplification and lack of activating mutations in metaplastic breast carcinomas</article-title><source>J Pathol</source><year>2006</year><volume>209</volume><fpage>445</fpage><lpage>453</lpage><pub-id pub-id-type="pmid">16739104</pub-id><pub-id pub-id-type="doi">10.1002/path.2004</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carvalho</surname><given-names>I</given-names></name><name><surname>Milanezi</surname><given-names>F</given-names></name><name><surname>Martins</surname><given-names>A</given-names></name><name><surname>Reis</surname><given-names>RM</given-names></name><name><surname>Schmitt</surname><given-names>F</given-names></name></person-group><article-title>Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression</article-title><source>Breast Cancer Res</source><year>2005</year><volume>7</volume><fpage>R788</fpage><lpage>R795</lpage><pub-id pub-id-type="pmid">16168125</pub-id><pub-id pub-id-type="doi">10.1186/bcr1304</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Longatto</surname><given-names>FA</given-names></name><name><surname>Costa</surname><given-names>SM</given-names></name><name><surname>Milanezi</surname><given-names>F</given-names></name><name><surname>Montruccoli</surname><given-names>D</given-names></name><name><surname>Montruccoli</surname><given-names>GC</given-names></name><name><surname>Baltazar</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>Immunohistochemical expression of VEGF-A and its ligands in non-neoplastic lesions of the breast sampling-assisted by dynamic angiothermography</article-title><source>Oncol Rep</source><year>2007</year><volume>18</volume><fpage>1201</fpage><lpage>1206</lpage><pub-id pub-id-type="pmid">17914573</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Basto</surname><given-names>D</given-names></name><name><surname>Trovisco</surname><given-names>V</given-names></name><name><surname>Lopes</surname><given-names>JM</given-names></name><name><surname>Martins</surname><given-names>A</given-names></name><name><surname>Pardal</surname><given-names>F</given-names></name><name><surname>Soares</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Mutation analysis of B-RAF gene in human gliomas</article-title><source>Acta Neuropathol (Berl)</source><year>2005</year><volume>109</volume><fpage>207</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">15791479</pub-id><pub-id pub-id-type="doi">10.1007/s00401-004-0936-x</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gomes</surname><given-names>AL</given-names></name><name><surname>Gouveia</surname><given-names>A</given-names></name><name><surname>Capelinha</surname><given-names>AF</given-names></name><name><surname>de la</surname><given-names>CD</given-names></name><name><surname>Silva</surname><given-names>P</given-names></name><name><surname>Reis</surname><given-names>RM</given-names></name><etal></etal></person-group><article-title>Molecular alterations of KIT and PDGFRA in GISTs: evaluation of a Portuguese series</article-title><source>J Clin Pathol</source><year>2008</year><volume>61</volume><fpage>203</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">17827398</pub-id><pub-id pub-id-type="doi">10.1136/jcp.2007.047043</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>NH</given-names></name><name><surname>Kim</surname><given-names>YB</given-names></name><name><surname>Park</surname><given-names>TK</given-names></name><name><surname>Kim</surname><given-names>GE</given-names></name><name><surname>Park</surname><given-names>K</given-names></name><name><surname>Song</surname><given-names>KJ</given-names></name></person-group><article-title>P63 and EGFR as prognostic predictors in stage IIB radiation-treated cervical squamous cell carcinoma</article-title><source>Gynecol Oncol</source><year>2003</year><volume>91</volume><fpage>346</fpage><lpage>353</lpage><pub-id pub-id-type="pmid">14599865</pub-id><pub-id pub-id-type="doi">10.1016/S0090-8258(03)00504-3</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kristensen</surname><given-names>GB</given-names></name><name><surname>Holm</surname><given-names>R</given-names></name><name><surname>Abeler</surname><given-names>VM</given-names></name><name><surname>Trope</surname><given-names>CG</given-names></name></person-group><article-title>Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study</article-title><source>Cancer</source><year>1996</year><volume>78</volume><fpage>433</fpage><lpage>440</lpage><pub-id pub-id-type="pmid">8697388</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1097-0142(19960801)78:3&#x0003c;433::AID-CNCR9&#x0003e;3.0.CO;2-K</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kersemaekers</surname><given-names>AM</given-names></name><name><surname>Fleuren</surname><given-names>GJ</given-names></name><name><surname>Kenter</surname><given-names>GG</given-names></name><name><surname>Broek</surname><given-names>LJ Van den</given-names></name><name><surname>Uljee</surname><given-names>SM</given-names></name><name><surname>Hermans</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis</article-title><source>Clin Cancer Res</source><year>1999</year><volume>5</volume><fpage>577</fpage><lpage>586</lpage><pub-id pub-id-type="pmid">10100709</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hale</surname><given-names>RJ</given-names></name><name><surname>Buckley</surname><given-names>CH</given-names></name><name><surname>Gullick</surname><given-names>WJ</given-names></name><name><surname>Fox</surname><given-names>H</given-names></name><name><surname>Williams</surname><given-names>J</given-names></name><name><surname>Wilcox</surname><given-names>FL</given-names></name></person-group><article-title>Prognostic value of epidermal growth factor receptor expression in cervical carcinoma</article-title><source>J Clin Pathol</source><year>1993</year><volume>46</volume><fpage>149</fpage><lpage>153</lpage><pub-id pub-id-type="pmid">8459036</pub-id><pub-id pub-id-type="doi">10.1136/jcp.46.2.149</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>GE</given-names></name><name><surname>Kim</surname><given-names>YB</given-names></name><name><surname>Cho</surname><given-names>NH</given-names></name><name><surname>Chung</surname><given-names>HC</given-names></name><name><surname>Pyo</surname><given-names>HR</given-names></name><name><surname>Lee</surname><given-names>JD</given-names></name><etal></etal></person-group><article-title>Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival</article-title><source>Clin Cancer Res</source><year>2004</year><volume>10</volume><fpage>1366</fpage><lpage>1374</lpage><pub-id pub-id-type="pmid">14977838</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-0497-03</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Shui</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Sheng</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Xue</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>EGFR and HER2 expression in primary cervical cancers and corresponding lymph node metastases: implications for targeted radiotherapy</article-title><source>BMC Cancer</source><year>2008</year><volume>8</volume><fpage>232</fpage><pub-id pub-id-type="pmid">18700025</pub-id><pub-id pub-id-type="doi">10.1186/1471-2407-8-232</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taguchi</surname><given-names>T</given-names></name><name><surname>Tsukuda</surname><given-names>M</given-names></name><name><surname>Imagawa-Ishiguro</surname><given-names>Y</given-names></name><name><surname>Kato</surname><given-names>Y</given-names></name><name><surname>Sano</surname><given-names>D</given-names></name></person-group><article-title>Involvement of EGFR in the response of squamous cell carcinoma of the head and neck cell lines to gefitinib</article-title><source>Oncol Rep</source><year>2008</year><volume>19</volume><fpage>65</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">18097577</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arias-Pulido</surname><given-names>H</given-names></name><name><surname>Joste</surname><given-names>N</given-names></name><name><surname>Chavez</surname><given-names>A</given-names></name><name><surname>Muller</surname><given-names>CY</given-names></name><name><surname>Dai</surname><given-names>D</given-names></name><name><surname>Smith</surname><given-names>HO</given-names></name><etal></etal></person-group><article-title>Absence of epidermal growth factor receptor mutations in cervical cancer</article-title><source>Int J Gynecol Cancer</source><year>2008</year><volume>18</volume><fpage>749</fpage><lpage>754</lpage><pub-id pub-id-type="pmid">17949425</pub-id><pub-id pub-id-type="doi">10.1111/j.1525-1438.2007.01111.x</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Straight</surname><given-names>SW</given-names></name><name><surname>Hinkle</surname><given-names>PM</given-names></name><name><surname>Jewers</surname><given-names>RJ</given-names></name><name><surname>McCance</surname><given-names>DJ</given-names></name></person-group><article-title>The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes</article-title><source>J Virol</source><year>1993</year><volume>67</volume><fpage>4521</fpage><lpage>4532</lpage><pub-id pub-id-type="pmid">8392596</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Srirangam</surname><given-names>A</given-names></name><name><surname>Potter</surname><given-names>DA</given-names></name><name><surname>Roman</surname><given-names>A</given-names></name></person-group><article-title>HPV16 E5 protein disrupts the c-Cbl-EGFR interaction and EGFR ubiquitination in human foreskin keratinocytes</article-title><source>Oncogene</source><year>2005</year><volume>24</volume><fpage>2585</fpage><lpage>2588</lpage><pub-id pub-id-type="pmid">15735736</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1208453</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goncalves</surname><given-names>A</given-names></name><name><surname>Fabbro</surname><given-names>M</given-names></name><name><surname>Lhomme</surname><given-names>C</given-names></name><name><surname>Gladieff</surname><given-names>L</given-names></name><name><surname>Extra</surname><given-names>JM</given-names></name><name><surname>Floquet</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer</article-title><source>Gynecol Oncol</source><year>2008</year><volume>108</volume><fpage>42</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">17980406</pub-id><pub-id pub-id-type="doi">10.1016/j.ygyno.2007.07.057</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lynch</surname><given-names>TJ</given-names></name><name><surname>Bell</surname><given-names>DW</given-names></name><name><surname>Sordella</surname><given-names>R</given-names></name><name><surname>Gurubhagavatula</surname><given-names>S</given-names></name><name><surname>Okimoto</surname><given-names>RA</given-names></name><name><surname>Brannigan</surname><given-names>BW</given-names></name><etal></etal></person-group><article-title>Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</article-title><source>N Engl J Med</source><year>2004</year><volume>20;350</volume><fpage>2129</fpage><lpage>2139</lpage><pub-id pub-id-type="pmid">15118073</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa040938</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taja-Chayeb</surname><given-names>L</given-names></name><name><surname>Chavez-Blanco</surname><given-names>A</given-names></name><name><surname>Martinez-Tlahuel</surname><given-names>J</given-names></name><name><surname>Gonzalez-Fierro</surname><given-names>A</given-names></name><name><surname>Candelaria</surname><given-names>M</given-names></name><name><surname>Chanona-Vilchis</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Expression of platelet derived growth factor family members and the potential role of imatinib mesylate for cervical cancer</article-title><source>Cancer Cell Int</source><year>2006</year><volume>6</volume><fpage>22</fpage><pub-id pub-id-type="pmid">17014709</pub-id><pub-id pub-id-type="doi">10.1186/1475-2867-6-22</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ryu</surname><given-names>SY</given-names></name><name><surname>Oka</surname><given-names>K</given-names></name><name><surname>Tsujii</surname><given-names>H</given-names></name><name><surname>Suzuki</surname><given-names>Y</given-names></name><name><surname>Nakano</surname><given-names>T</given-names></name></person-group><article-title>Platelet-derived endothelial cell growth factor as a prognostic factor for radiotherapy outcome in patients with adenocarcinoma of the uterine cervix</article-title><source>Gynecol Oncol</source><year>2003</year><volume>89</volume><fpage>414</fpage><lpage>419</lpage><pub-id pub-id-type="pmid">12798704</pub-id><pub-id pub-id-type="doi">10.1016/S0090-8258(03)00081-7</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pietras</surname><given-names>K</given-names></name><name><surname>Pahler</surname><given-names>J</given-names></name><name><surname>Bergers</surname><given-names>G</given-names></name><name><surname>Hanahan</surname><given-names>D</given-names></name></person-group><article-title>Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting</article-title><source>PLoS Med</source><year>2008</year><volume>5</volume><fpage>e19</fpage><pub-id pub-id-type="pmid">18232728</pub-id><pub-id pub-id-type="doi">10.1371/journal.pmed.0050019</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kummel</surname><given-names>S</given-names></name><name><surname>Heidecke</surname><given-names>H</given-names></name><name><surname>Brock</surname><given-names>B</given-names></name><name><surname>Denkert</surname><given-names>C</given-names></name><name><surname>Hecktor</surname><given-names>J</given-names></name><name><surname>Koninger</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>[Imatinib &#x02013; a possible therapeutic option for cervical carcinoma: results of a preclinical phase I study]</article-title><source>Gynakol Geburtshilfliche Rundsch</source><year>2008</year><volume>48</volume><fpage>94</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">18431049</pub-id><pub-id pub-id-type="doi">10.1159/000119032</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>M</given-names></name><name><surname>Turley</surname><given-names>H</given-names></name><name><surname>Cook</surname><given-names>N</given-names></name><name><surname>Pezzella</surname><given-names>F</given-names></name><name><surname>Pillai</surname><given-names>G</given-names></name><name><surname>Ogilvie</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>The angiogenic receptor KDR is widely distributed in human tissues and tumours and relocates intracellularly on phosphorylation. An immunohistochemical study</article-title><source>Histopathology</source><year>2003</year><volume>43</volume><fpage>33</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">12823710</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2559.2003.01644.x</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Giatromanolaki</surname><given-names>A</given-names></name><name><surname>Koukourakis</surname><given-names>MI</given-names></name><name><surname>Turley</surname><given-names>H</given-names></name><name><surname>Sivridis</surname><given-names>E</given-names></name><name><surname>Harris</surname><given-names>AL</given-names></name><name><surname>Gatter</surname><given-names>KC</given-names></name></person-group><article-title>Phosphorylated KDR expression in endometrial cancer cells relates to HIF1alpha/VEGF pathway and unfavourable prognosis</article-title><source>Mod Pathol</source><year>2006</year><volume>19</volume><fpage>701</fpage><lpage>707</lpage><pub-id pub-id-type="pmid">16557278</pub-id><pub-id pub-id-type="doi">10.1038/modpathol.3800579</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>SB</given-names></name><name><surname>Turley</surname><given-names>H</given-names></name><name><surname>Cheale</surname><given-names>M</given-names></name><name><surname>Blazquez</surname><given-names>C</given-names></name><name><surname>Roberts</surname><given-names>H</given-names></name><name><surname>James</surname><given-names>N</given-names></name><etal></etal></person-group><article-title>Phosphorylated KDR is expressed in the neoplastic and stromal elements of human renal tumours and shuttles from cell membrane to nucleus</article-title><source>J Pathol</source><year>2004</year><volume>202</volume><fpage>313</fpage><lpage>320</lpage><pub-id pub-id-type="pmid">14991896</pub-id><pub-id pub-id-type="doi">10.1002/path.1520</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>R</given-names></name><name><surname>Ye</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Yan</surname><given-names>Q</given-names></name><name><surname>Barsky</surname><given-names>SH</given-names></name><name><surname>Gao</surname><given-names>JX</given-names></name></person-group><article-title>Precancerous stem cells can serve as tumor vasculogenic progenitors</article-title><source>PLoS ONE</source><year>2008</year><volume>3</volume><fpage>e1652</fpage><pub-id pub-id-type="pmid">18286204</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0001652</pub-id></citation></ref><ref id="B46"><citation citation-type="other"><article-title>A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer</article-title><year>2008</year><ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/record/NCT00510250"/></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Faivre</surname><given-names>S</given-names></name><name><surname>Djelloul</surname><given-names>S</given-names></name><name><surname>Raymond</surname><given-names>E</given-names></name></person-group><article-title>New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors</article-title><source>Semin Oncol</source><year>2006</year><volume>33</volume><fpage>407</fpage><lpage>420</lpage><pub-id pub-id-type="pmid">16890796</pub-id><pub-id pub-id-type="doi">10.1053/j.seminoncol.2006.04.005</pub-id></citation></ref><ref id="B48"><citation citation-type="other"><article-title>National Ovarian Cancer Coalition Dallas &#x02013; Ft Worth Chapter</article-title><year>2008</year><ext-link ext-link-type="uri" xlink:href="http://www.dfwovarian.org/clinical_trials.html"/></citation></ref></ref-list></back></article> 